Refractory Glaucoma News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Myra Vision, A Shifamed Portfolio Company, Closes $17M In Series A Financings Company to accelerate development of the first-of-its-kind treatment for patients with moderate to severe glaucoma News provided by Share this article Share this article CAMPBELL, Calif., June 1, 2021 /PRNewswire/ -- Myra Vision, a Shifamed portfolio company, announced today the closing of its $17M Series A financings, which will be used to advance product development, scale infrastructure, and expand their team in order to support the development of the first of its kind glaucoma treatment device. The financings ...

Published: Apr 28, 2021     DURHAM, N.C.--(BUSINESS WIRE)-- Aerie Pharmaceuticals, Inc.. (NASDAQ: AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, ocular surface diseases and retinal diseases, today announced it will participate and have poster presentations at the virtual Association for Research and Vision in Ophthalmology (ARVO) Annual Meeting, to be held May 1-7, 2021. The posters will highlight topics ranging from additional research findings on...

Press release content from Business Wire. The AP news staff was not involved in its creation. Aerie Pharmaceuticals Announces Presentations at the 2021 Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting April 28, 2021 GMT DURHAM, N.C.--(BUSINESS WIRE)--Apr 28, 2021-- Aerie Pharmaceuticals, Inc. (NASDAQ: AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, ocular surface diseases and retinal diseases, today announced it will participate ...